Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Glass, NY
Andrew B. Glass, Dix Hills, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20100041000 | System and Method for Controlling the Presentation of Material and Operation of External Devices - By performing a comparison of words spoken by a speaker and defined material which is presented to the speaker, information can be determined which allows for the convenient control of the presentation of material and external devices. A comparison of a speaker's words with defined material can be beneficially used as an input for controlling the operation of an exercise apparatus, video games, material presented to an audience, and the presentation of the material itself. Similar feedback loops can also be used with measurement and stimulation of neurophysiologic states, to make the activity of reading more enjoyable and convenient, or for other purposes. | 02-18-2010 |
David Glass, Corlandt Manor, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20090192087 | Methods and Compositions Using Klotho-FGF Fusion Polypeptides - The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. | 07-30-2009 |
David J. Glass, Cortlandt Manor, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20080199479 | Method of treating a muscle-related condition with modified IGF1 polypeptides - A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy. | 08-21-2008 |
| 20090069235 | IGF-1 Fusion Polypeptides and Therapeutic Uses Thereof - A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1. | 03-12-2009 |
| 20090175864 | IGF-1 AND IGF-2 CHIMERIC POLYPEPTIDES AND THERAPEUTIC USES THEREOF - Pharmaceutical compositions containing a chimeric protein comprising an IGF1 and an IGF2 component and optionally (F), a fusion component, and/or a signal sequence, are provided. The chimeric protein exhibits improved activity relative to the native IGF1 or IGF2 polypeptide. Further, therapeutic methods for treating IGF1 insufficiency diseases or conditions using the pharmaceutical compositions of the invention are also provided. The diseases or conditions treatable with the methods include muscle atrophy as a result of, for example, aging, cachexia, rheumatoid arthritis, diabetes, disuse or immobilization of muscle, and the like, as well as dwarfism and myocardial infarction. | 07-09-2009 |
| 20110020342 | IGF-1 FUSION POLYPEPTIDES AND THERAPEUTIC USES THEREOF - A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia. | 01-27-2011 |
David Jonathan Glass, Cambridge, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20100234290 | Stabilized Insulin-like Growth Factor Polypeptides - The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented. | 09-16-2010 |
David Jonathan Glass, Cortlandt Manor, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20100173839 | STABILIZED INSULIN-LIKE GROWTH FACTOR POLYPEPTIDES - The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented. | 07-08-2010 |
John D. Glass, Shoreham, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20090069230 | GDNF-DERIVED PEPTIDES - Compositions that include peptides derived from glial-derived neurotrophic factor (GDNF) (e.g., substantially pure polypeptides comprising a fragment of a GDNF precursor protein) and biologically active variants thereof are provided. The compositions can include one or more types of peptides and can include other substances (e.g., pharmaceutically acceptable carriers or diluents or liposomes). Also provided are methods for using the compositions for treatment of neurological disorders (e.g., motor system disorders and sensory system disorders). | 03-12-2009 |
| 20100035820 | AMIDATED DOPAMINE NEURON STIMULATING PEPTIDES FOR CNS DOPAMINERGIC UPREGULATION - The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies. | 02-11-2010 |
| 20100184692 | Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation - The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies. | 07-22-2010 |
Michael Glass, Farmingville, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20100232554 | PREDICTIVE SIGNAL CANCELLATION FOR EXTRACTING 1 MB/s MIL-STD-1553 COMPONENT FROM COMPOSITE HIGH PERFORMANCE 1553 SIGNAL - Method and apparatus for maximizing the usable bandwidth for High Performance 1553 terminals operating concurrently on the same physical bus with legacy 1 Mb/s MIL-STD-1553 terminals. More specifically, the method and apparatus provides implementation for predictive cancellation by synthesizing an estimate of the 1 Mb/s MIL-STD-1553 component of a composite 1 Mb/s plus High Performance 1553 input signal using either of two different techniques: (1) a combination of digital and analog techniques; and (2) an all digital technique. The synthesized signal is then subtracted from the composite signal. Both techniques employ an algorithm for minimizing the effects of clock skew between 1 Mb/s 1553 transmitting clocks and the local High Performance 1553 sampling clock. Both techniques also incorporate an adaptation algorithm for developing and maintaining digital models of 1 Mb/s 1553 signals received from multiple 1 Mb/s 1553 terminals on a bus. | 09-16-2010 |